Visceral and subcutaneous fat in patients treated with olanzapine: a case series
Objectives: - We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome. - Methods: - Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2010
|
| In: |
Clinical neuropharmacology
Year: 2010, Volume: 33, Issue: 5, Pages: 248-249 |
| ISSN: | 1537-162X |
| DOI: | 10.1097/WNF.0b013e3181f0ec33 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1097/WNF.0b013e3181f0ec33 Verlag: https://journals.lww.com/clinicalneuropharm/Abstract/2010/09000/Visceral_and_Subcutaneous_Fat_in_Patients_Treated.7.aspx 
|
| Author Notes: | Maria Gilles, Frank Hentschel, Georgios Paslakis, Valerie Glahn, Florian Lederbogen, Michael Deuschle |
| Summary: | Objectives: - We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome. - Methods: - Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glucose, and lipids in an unselected population of 14 schizophrenic patients. - Results: - We found a 6-week olanzapine treatment to be related to increased body mass index and proportion of total fat at the level of the fourth vertebral body. - Conclusions: - On the basis of these findings, we conclude that weight gain after a 6-week olanzapine treatment is partly attributable to increased visceral fat and may thus contribute to metabolic syndrome. |
|---|---|
| Item Description: | Gesehen am 15.10.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1537-162X |
| DOI: | 10.1097/WNF.0b013e3181f0ec33 |